GIP/GLP-1 Dual Agonists Adverse-Event Management Protocols

Tirzepatide is labeled as an agonist at both the GIP and GLP-1 receptors, which is what makes it a dual agonist rather than a pure GLP-1 drug [1][4]. Where a warning below comes from the Wegovy or Foundayo label rather than a tirzepatide label, the product is named.

Which side effects are most common?

The Zepbound weight-management trials give the clearest numbers at the top dose. At 15 mg, nausea was reported by 28% of patients against 8% on placebo, diarrhea by 23% against 8%, vomiting by 13% against 2%, and constipation by 11% against 5% [1]. Across those trials, 6.7% of patients on 15 mg stopped treatment because of an adverse reaction, compared with 3.4% on placebo [1]. Hair loss was reported by 4% to 5% versus 1%; the GLP-1 labels link it to weight reduction and report it more often in women [1][2][3].

Rates from different trials and different populations are not directly comparable, and the labels say so [2].

Why is the dose stepped up slowly?

Gastrointestinal effects are the common class effect and are worst during dose escalation [1][2][3]. Current GLP-1 labels, including Wegovy and Foundayo, start at a low dose and step up over weeks to reduce gastrointestinal side effects [2][3].

What helps with nausea and vomiting?

The labels' own tool is the slow step-up described above. Ginger is often mentioned, but the review usually cited for it covered nausea and vomiting in pregnancy and with chemotherapy, not GLP-1 drugs [5].

The labels also address the severe end of the spectrum. Severe gastrointestinal reactions are a concern with GLP-1 treatments, and the Wegovy and Foundayo labels state those products are not recommended in people with severe gastroparesis [2][3]. The labels do not say that GLP-1 drugs cause gastroparesis [2][3].

What do the labels say about pancreatitis and gallbladder disease?

The Wegovy and Foundayo labels say acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has been observed in patients treated with GLP-1 receptor agonists, and to discontinue the drug if pancreatitis is suspected [2][3]. The Wegovy label describes symptoms as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [2].

Acute gallbladder disease is a separate labeled class warning; the Wegovy label says that if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated [2].

Who is at risk of hypoglycemia?

GLP-1 drugs stimulate insulin release in a glucose-dependent manner. Even so, the Wegovy and Foundayo labels warn that hypoglycemia, including severe hypoglycemia, becomes more likely when the drug is combined with insulin or an insulin secretagogue, and they say reducing the dose of the insulin or secretagogue may be necessary [2][3]. The Wegovy label tells patients with diabetes to monitor blood glucose before starting and during treatment [2].

Dehydration and kidney injury

Acute kidney injury from volume depletion is a labeled warning. The Foundayo label says the majority of reported events occurred in patients whose nausea, vomiting or diarrhea led to dehydration, and the Wegovy and Foundayo labels say to monitor renal function in patients reporting reactions that could lead to volume depletion [2][3].

What else on the label matters during treatment?

The tirzepatide boxed warning covers thyroid C-cell tumors seen in rodents, states that human relevance is unknown, and contraindicates the drug in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1][4]. Serious hypersensitivity reactions, including anaphylaxis and angioedema, are a class warning, and the Wegovy label says to stop the drug and seek medical attention promptly if one is suspected [2].

Resting heart rate rises by a mean of 1 to 3 bpm on tirzepatide [1]; the Wegovy label advises monitoring heart rate at regular intervals [2]. Diabetic retinopathy complications are a labeled warning in people with type 2 diabetes, and patients with a history of retinopathy should be monitored [2]. Rare postmarketing reports describe pulmonary aspiration during general anesthesia or deep sedation in patients receiving GLP-1 receptor agonists, and patients are told to inform their healthcare providers of planned surgeries or procedures [2].

Tirzepatide's contraindications include a personal or family history of medullary thyroid carcinoma, MEN 2, and prior serious hypersensitivity to tirzepatide or its ingredients [1]. Weight-loss treatment offers no benefit during pregnancy, and the label advises stopping when pregnancy is recognized [1].

Oral contraceptives and other oral medicines

The tirzepatide label advises switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after starting and after each dose increase [1]. Semaglutide labels carry no such advice, and a study of oral semaglutide tablets found no clinically significant change in ethinyl estradiol or levonorgestrel [2].

More generally, the class delays gastric emptying and can change the absorption of oral medicines, so the labels advise closer monitoring for drugs with a narrow therapeutic index [1][2][3]. With the oral semaglutide tablet, levothyroxine exposure rose 33% [2].